Announcements Trials
Browse Landscape

Phase

Phase 3 6Phase 2/3 1Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Recurrence 1Optic Neuritis 1Neuromyelitis Optica 1Myelitis, Transverse 1Demyelinating Diseases 1

Interventions

Cisplatin 29Carboplatin 28Gemcitabine 27Paclitaxel 26pembrolizumab 24Capecitabine 16Pemetrexed 15Bevacizumab 15Docetaxel 14Oxaliplatin 13Fluorouracil 12Drug Therapy 12Nivolumab 10130-nm albumin-bound paclitaxel 9Trastuzumab 8anlotinib 7Injections 7Rituximab 6venetoclax 5atezolizumab 5Temozolomide 5Leucovorin 5Ipilimumab 5Lenalidomide 4Irinotecan 4Interferon alpha-2 4Folfox protocol 4Dexamethasone 4Azacitidine 4Albumin-Bound Paclitaxel 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × INDUSTRY × eculizumab × Clear all
NCT04155424 2024-09-25

A Study of the Safety and Activity of Eculizumab in Pediatric Participants With Relapsing Neuromyelitis Optica Spectrum Disorder

Alexion Pharmaceuticals, Inc.

Phase 2/3 Terminated
5 enrolled 15 charts

Demyelinating Diseases, Myelitis, Transverse, Neuromyelitis Optica, Optic Neuritis, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡